102 related articles for article (PubMed ID: 20200393)
21. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Bani-Sadr F; Palmer P; Scieux C; Molina JM
Clin Infect Dis; 2004 Oct; 39(7):1062-4. PubMed ID: 15472862
[TBL] [Abstract][Full Text] [Related]
22. Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Ala A; Dieterich DT
AIDS Read; 2004 Mar; 14(3):134-5. PubMed ID: 15068001
[No Abstract] [Full Text] [Related]
23. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
24. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Kagan RM; Merigan TC; Winters MA; Heseltine PN
Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
[No Abstract] [Full Text] [Related]
25. [Medication change due to side effects or possible long-term complications. Side effect management with vision].
Sankawa Y
MMW Fortschr Med; 2009 Apr; 151(18):35. PubMed ID: 19769072
[No Abstract] [Full Text] [Related]
26. Vaccine briefs.
McEnery R; Kresge KJ
IAVI Rep; 2010; 14(6):18-9. PubMed ID: 21384772
[No Abstract] [Full Text] [Related]
27. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
28. 96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
[No Abstract] [Full Text] [Related]
29. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
30. Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
Nishijima T; Tsukada K; Nagata N; Watanabe K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
AIDS; 2011 Aug; 25(13):1677-9. PubMed ID: 21811107
[No Abstract] [Full Text] [Related]
31. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
[No Abstract] [Full Text] [Related]
32. Study shows people can safely switch to Atripla.
Proj Inf Perspect; 2008 Dec; (47):2. PubMed ID: 19226673
[No Abstract] [Full Text] [Related]
33. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
35. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
de Vries-Sluijs TE; van der Eijk AA; Hansen BE; Osterhaus AD; de Man RA; van der Ende ME
J Clin Virol; 2006 May; 36(1):60-3. PubMed ID: 16418013
[TBL] [Abstract][Full Text] [Related]
36. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
37. [HIV preexposure prophylaxis].
Olczak A; Grabczewska E
Przegl Epidemiol; 2012; 66(1):79-82. PubMed ID: 22708303
[TBL] [Abstract][Full Text] [Related]
38. Clinical decisions. Preexposure prophylaxis for HIV prevention.
Abdool Karim SS; Gray GE; Martinson N
N Engl J Med; 2012 Aug; 367(5):462-5. PubMed ID: 22784042
[No Abstract] [Full Text] [Related]
39. Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.
Frange P; Blanche S; Chaix ML
J Antimicrob Chemother; 2013 Nov; 68(11):2694-5. PubMed ID: 23743089
[No Abstract] [Full Text] [Related]
40. HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.
Cohen J
Science; 2010 Dec; 330(6009):1298-9. PubMed ID: 21127220
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]